首页> 外文期刊>Journal of neurogenetics >Toward the Identification of Peripheral Epigenetic Biomarkers of Schizophrenia
【24h】

Toward the Identification of Peripheral Epigenetic Biomarkers of Schizophrenia

机译:精神分裂症周围表观遗传标记的鉴定

获取原文
获取原文并翻译 | 示例
           

摘要

Schizophrenia (SZ) is a heritable, nonmendelian, neurodevelopmental disorder in which epigenetic dysregulation of the brain genome plays a fundamental role in mediating the clinical manifestations and course of the disease. The authors recently reported that two enzymes that belong to the dynamic DNA methylation/demethylation network-DNMT (DNA methyltransferase) and TET (ten-eleven translocase; 5-hydroxycytosine translocator)-are abnormally increased in corticolimbic structures of SZ postmortem brain, suggesting a causal relationship between clinical manifestations of SZ and changes in DNA methylation and in the expression of SZ candidate genes (e. g., brain-derived neurotrophic factor [BDNF], glucocorticoid receptor [GCR], glutamic acid decarboxylase 67 [GAD67], reelin). Because the clinical manifestations of SZ typically begin with a prodrome followed by a first episode in adolescence with subsequent deterioration, it is obvious that the natural history of this disease cannot be studied only in postmortem brain. Hence, the focus is currently shifting towards the feasibility of studying epigenetic molecular signatures of SZ in blood cells. Initial studies show a significant enrichment of epigenetic changes in lymphocytes in gene networks directly relevant to psychiatric disorders. Furthermore, the expression of DNA-methylating/demethylating enzymes and SZ candidate genes such as BDNF and GCR are altered in the same direction in both brain and blood lymphocytes. The coincidence of these changes in lymphocytes and brain supports the hypothesis that common environmental or genetic risk factors are operative in altering the epigenetic components involved in orchestrating transcription of specific genes in brain and peripheral tissues. The identification of DNA methylation signatures for SZ in peripheral blood cells of subjects with genetic and clinical high risk would clearly have potential for the diagnosis of SZ early in its course and would be invaluable for initiating early intervention and individualized treatment plans.
机译:精神分裂症(SZ)是一种可遗传的非孟德尔神经发育障碍,其中脑基因组的表观遗传失调在介导该疾病的临床表现和病程中起着基本作用。作者最近报道说,属于动态DNA甲基化/去甲基化网络的两种酶-DNMT(DNA甲基转移酶)和TET(十一个11个转位酶; 5-羟基胞嘧啶移位子)在SZ死后大脑皮质结构中异常增加。 SZ临床表现与DNA甲基化变化和SZ候选基因表达之间的因果关系(例如,脑源性神经营养因子[BDNF],糖皮质激素受体[GCR],谷氨酸脱羧酶67 [GAD67],reelin)。由于SZ的临床表现通常始于前驱,然后是青春期的第一发作,随后恶化,因此很明显,仅在死后大脑中不能研究这种疾病的自然史。因此,目前的重点是转向研究血细胞中SZ的表观遗传分子标记的可行性。初步研究表明,与精神疾病直接相关的基因网络中淋巴细胞的表观遗传学变化显着丰富。此外,在大脑和血液淋巴细胞中,DNA甲基化/去甲基化酶和SZ候选基因(如BDNF和GCR)的表达沿相同方向改变。淋巴细胞和大脑中这些变化的巧合支持了这样的假说,即常见的环境或遗传风险因素可有效改变参与协调大脑和周围组织中特定基因转录的表观遗传成分。具有遗传和临床高风险受试者的外周血细胞中SZ的DNA甲基化标记的鉴定显然具有在SZ病程早期诊断SZ的潜力,并且对于启动早期干预和个体化治疗计划具有不可估量的价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号